Bipolar Medications: Mechanisms of Action

Husseini K. Manji · Charles L. Bowden · Robert H. Belmaker

2008年11月 · American Psychiatric Pub

電子書

456

頁

評分和評論未經驗證瞭解詳情

關於本電子書

Lithium, the treatment of choice for mania since its usefulness was first reported, has been shown to have varied effects on multiple biological systems, including electrolyte flux and neurochemistry. Recent advances in cellular and molecular biology promise to provide clinicians with a better understanding of the etiology of bipolar disorder and new options for treatment.

Bipolar Medications: Mechanisms of Action presents the treatment and prophylaxis of bipolar disorder. More than 40 investigators share research and insight into the neurobiological mechanisms that help to explain the powerful effects of new antibipolar drugs. This comprehensive text Examines valproic acid, lamotrigine, inositol monophosphatase inhibitors, and protein kinase C inhibitors that have the potential to revolutionize clinical practice and provide new hypotheses on the etiology of bipolar disorder

Presents the current understanding of the cellular mechanisms of action of mood-stabilizing agents

Discusses the emergence of valproate as a powerful lithium alternative and examines the preliminary indications that lamotrigine will be an effective option

Examines the issue of withdrawal rebound, which can make lithium ineffective or even counterproductive, and reviews inositol monophosphatase inhibitors that mimic lithium action in patients

Compares lithium, carbamazepine, and valproate and their differential mechanisms, which could form the basis of a "rational polypharmacy" of manic depressive illness

Examines behavioral models important in the screening of new antibipolar compounds and the effects of antibipolar compounds on immediate early genes

Complete with extensive references, tables, and figures, this text is essential reading for any clinician who treats patients with bipolar disorder. It thoroughly documents the latest in psychopharmacology, as well as projecting future advances in the treatment of bipolar disorder.

關於作者

Husseini K. Manji, M.D., F.R.C.P.C., is Director of the Laboratory of Molecular Pathophysiology in the Department of Psychiatry and Behavioral Neurosciences at Wayne State University School of Medicine in Detroit, Michigan.

Charles L. Bowden, M.D., is the Nancy U. Karren Professor and Interim Chair of the Department of Psychiatry at the University of Texas Health Science Center at San Antonio, In San Antonio, Texas.

Robert H. Belmaker, M.D., is Hoffer-Vickar Professor of Psychiatry at Beer Sheva Mental Health Center and on the Faculty of Health Sciences at the Ben Gurion University of the Negev in Beersheva, Israel.